Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India (Q28550454)

7

0 references

author name string

V Ramesh

1

0 references

Kumar Avishek

3

0 references

Aditya Verma

4

0 references

Deepak Kumar Deep

5

0 references

Sandeep Verma

PLoS Neglected Tropical Diseases

6

0 references

language of work or name

English

0 references

publication date

2015

0 references

published in

0 references

volume

9

0 references

issue

10

0 references

page(s)

e0004093

0 references

copyright license

Creative Commons Attribution 4.0 International

start time

22 October 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Post-kala-azar dermal leishmaniasis: a histopathological study

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Nodular post-kala-azar dermal leishmaniasis: a distinct histopathological entity

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Drug resistance in leishmaniasis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Miltefosine to treat leishmaniasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Oral miltefosine for Indian visceral leishmaniasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Post-kala-azar dermal leishmaniasis in HIV-coinfected individuals: problems in diagnosis and treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Leishmania resistance to miltefosine associated with genetic marker

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.

3 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0004093

Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0004093

Increased parasite surface antigen-2 expression in clinical isolates of Leishmania donovani augments antimony resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0004093

Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0004093

Reliable diagnosis of post-kala-azar dermal leishmaniasis (PKDL) using slit aspirate specimen to avoid invasive sampling procedures.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4619646

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis

27 November 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0004093

Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0004093

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26492039

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26492039

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PNTD.0004093

1 reference

1 reference

1 reference

PubMed publication ID

26492039

1 reference